Zai Lab Posts Q2 2026 Revenue $106.3M, Net Loss $50.8M; Pipeline Milestones Set for H2

Zai Lab reported its Q2 2026 financial results, showing total revenue of $106.3 million and a net loss of $50.8 million.

The company's product revenue was $105.8 million, an increase of 11% sequentially from the prior quarter.

Research and development expenses rose to $61.8 million, while selling, general, and administrative expenses were $72.9 million.

Zai Lab's pipeline continues to advance with multiple global oncology and immunology programs. Key milestones include the planned initiation of a registrational Phase 3 trial for Zoci in first-line small cell lung cancer (SCLC) in H2 2026, as well as the ongoing enrollment in DLLEVATE, a registrational Phase 3 study in second-line-plus SCLC.

The company also announced regulatory designations for Zoci, including FDA Orphan Drug Designation for NECs and EMA Orphan Drug Designation for pulmonary NECs. Additionally, partner Amgen initiated enrollment in a global Phase 1b combination study.